Combined PAR4 antagonism and factor Xa inhibition, therefore, has potential additive therapeutic efficacy that merits further clinical investigation to reduce arterial thrombosis and atherothrombotic events. The gene discussed is F2RL3; the disease is deep vein thrombosis.